ADVENTRX to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on May 5.
A link to the Company's live audio webcast and slide presentation will be available via the "Investors" section of the Company's Web site at http://www.adventrx.com/investors/events.htm. An archived presentation will be available for 30 days.
The conference will be held at the InterContinental Hotel in Paris. To register for this conference or for additional information, visit www.rodmanandrenshaw.com. Attendees will include institutional investors and venture capitalists.
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance of existing drugs and address significant problems such as drug metabolism, bioavailability and resistance. More information can be found on the Company's Web site at www.adventrx.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's last annual report on Form 10-KSB, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 28, 2005|
|Previous Article:||Santarus Submits New Drug Application for ZEGERID Capsules; NDA for First Immediate-Release PPI Capsule Submitted Ahead of Previously Announced Third...|
|Next Article:||Vodafone Spain Expands BlackBerry Offering.|